Kang H, Gillespie T, Goodman M, Brodie SA, Brandes M, Ribeiro M, Khuri FR, Ramalingam SS, Shin DM, Brandes JC. Long-term use of valproic acid in United States Veterans is associated with reduced risk of smoking related head and neck cancers. Cancer 2014;120(9):1394-1400
Brodie SA, Li G, El-Kommos A, Kang H, Ramalingam SS, Behera M, Gandhi K, Kowalski J, Sica GL, Khuri FR, Vertino PM, Brandes JC. Class I HDACs are mediators of smoke carcinogen-induced stabilization of DNMT1 and serve as promising targets for chemoprevention of lung cancer. Cancer Prev Res (Phila). 2014;7(3):351-61
Kim WY, Kim MJ, Moon H, Yuan P, Kim JS, Woo JK, Zhang G, Suh YA, Feng L, Behrens C, Van Pelt CS, Kang H, Lee JJ, Hong WK, Wistuba II, Lee HY. Differential impacts of insulin-like growth factor-binding protein-3 (IGFBP-3) in epithelial IGF-induced lung cancer development. Endocrinology 2011;152(6):2164-73
Kang H, Kauh JS. Chemotherapy in the treatment of metastatic gastric cancer: Is there a global standard? Curr Treat Options Oncol 2011;12(1):96-106
Kang H, Rha SY, Oh KW, Nam CM. Greentea consumption and stomach cancer risk: A meta-analysis. Epidemiology Health 2010; 32:e2010001
Ahn EM, Song JI, Kang H, Park JJ, Yoo SH, Huh BR. The Symptom Expression and the Illness Behavior of North Korean Defectors: Toward an Effective Therapeutic Relationships. J Korean Acad Fam Med 2007; 28(5): 352-358
Kim H, Kim EK, Choi ES, Kim YJ, Lee HJ, Kim JJ, Jang HS, Shim KS, Jeon SN, Kang YH, Kang H, Oh J, Cho KS, Kwon S. The Determinants of Adolescent Smoking by Sex and School Type in Korea. J Prev Med Public Health 2006;39(5):379-88
Donato NJ, Perez M, Kang H, Siddik ZH, Ling YH, Perez-Soler R. EGF Receptor and p21waf1 Expression are Reciprocally Altered as ME-180 Cervical Carcinoma Cells Progress from High to Low Cisplatin Sensitivity. Clin Cancer Res 2000;6(1):193-202
1. A phase 1 study of IMGN289 in adult patients with EGFR-positive solid tumors.
2. A randomized, double-blind, placebo-controlled study of chemotherapy plus cetuximab in combination with VTX-2337 in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.